3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $596817 | -$8M | 28.1% | -883.3% | -$8M | — | $6M |
| 2024 | $510360 | -$1M | 30.4% | -286.5% | -$1M | — | $3M |
| 2023 | $350131 | $13560 | 43.8% | -2.8% | -$55947 | — | — |
How the market has priced YDES against its own fundamentals since 2025-08 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, YD Bio Ltd's revenue has grown 30.6% per year. These are computed facts, not advice.
As of FY2025, YD Bio Ltd reported — of total debt against $6M of cash.
In FY2025, gross margin was 28.1%, operating margin -883.3%, and net margin -1392.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.